Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307264934> ?p ?o ?g. }
- W4307264934 endingPage "1305" @default.
- W4307264934 startingPage "1305" @default.
- W4307264934 abstract "Thyroid eye disease (TED) is the most common orbital disease in adults. Targeting expanded orbital adipose tissue (OAT) removed by surgery has therapeutic potential. However, drugs targeting OAT are unavailable because of the lack of deciphering features of OAT. Here, we aimed to investigate the mechanism underlying OAT expansion and identify a drug targeting OAT in TED. We found an increasing number of adipocytes with smaller size in TED-derived OATs as compared with controls, indicating that hyperplasia rather than hypertrophy contributed to OAT enlargement in TED. Typically smaller-sized adipocytes in TED patient-derived OATs were noted to localize surrounding vessels. RNA sequencing revealed enriched vascular endothelial growth factor receptor (VEGFR) genes in adipocytes differentiated from preadipocytes of TED-derived stromal vascular fraction (SVF). Similarly, OATs in patients with TED also expressed a higher level of VEGFR-1 and -2. We induced adipogenesis in TED-derived SVF with or without Lenvatinib, an FDA-approved small-molecule VEGFR inhibitor. Lenvatinib significantly suppressed lipid accumulation in a dose-dependent manner. In conclusion, our study revealed the potential anti-adipogenic effect of Lenvatinib on the OAT of TED-affected patients. In addition to proposing a drug for TED treatment, this study shows the therapeutic potential of anti-adipogenesis drugs targeting the VEGF pathway." @default.
- W4307264934 created "2022-10-31" @default.
- W4307264934 creator A5011090841 @default.
- W4307264934 creator A5027986193 @default.
- W4307264934 creator A5030908494 @default.
- W4307264934 creator A5060412535 @default.
- W4307264934 creator A5074343111 @default.
- W4307264934 creator A5083228843 @default.
- W4307264934 date "2022-10-22" @default.
- W4307264934 modified "2023-10-15" @default.
- W4307264934 title "Repurposing Lenvatinib as A Potential Therapeutic Agent against Thyroid Eye Disease by Suppressing Adipogenesis in Orbital Adipose Tissues" @default.
- W4307264934 cites W1967792499 @default.
- W4307264934 cites W1989020172 @default.
- W4307264934 cites W1999239339 @default.
- W4307264934 cites W2000292756 @default.
- W4307264934 cites W2000708596 @default.
- W4307264934 cites W2011291547 @default.
- W4307264934 cites W2027442301 @default.
- W4307264934 cites W2030519794 @default.
- W4307264934 cites W2042397891 @default.
- W4307264934 cites W2044021940 @default.
- W4307264934 cites W2050717908 @default.
- W4307264934 cites W2056815794 @default.
- W4307264934 cites W2072032096 @default.
- W4307264934 cites W2082596386 @default.
- W4307264934 cites W2091774189 @default.
- W4307264934 cites W2092566647 @default.
- W4307264934 cites W2092684785 @default.
- W4307264934 cites W2101736025 @default.
- W4307264934 cites W2104085328 @default.
- W4307264934 cites W2137390873 @default.
- W4307264934 cites W2139716106 @default.
- W4307264934 cites W2163219777 @default.
- W4307264934 cites W2174893517 @default.
- W4307264934 cites W2317861010 @default.
- W4307264934 cites W2321550529 @default.
- W4307264934 cites W2555392192 @default.
- W4307264934 cites W2783249679 @default.
- W4307264934 cites W2794774404 @default.
- W4307264934 cites W2892045363 @default.
- W4307264934 cites W2908320623 @default.
- W4307264934 cites W2921434986 @default.
- W4307264934 cites W3086033711 @default.
- W4307264934 cites W3180908804 @default.
- W4307264934 cites W3209142043 @default.
- W4307264934 doi "https://doi.org/10.3390/ph15111305" @default.
- W4307264934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36355477" @default.
- W4307264934 hasPublicationYear "2022" @default.
- W4307264934 type Work @default.
- W4307264934 citedByCount "2" @default.
- W4307264934 countsByYear W43072649342023 @default.
- W4307264934 crossrefType "journal-article" @default.
- W4307264934 hasAuthorship W4307264934A5011090841 @default.
- W4307264934 hasAuthorship W4307264934A5027986193 @default.
- W4307264934 hasAuthorship W4307264934A5030908494 @default.
- W4307264934 hasAuthorship W4307264934A5060412535 @default.
- W4307264934 hasAuthorship W4307264934A5074343111 @default.
- W4307264934 hasAuthorship W4307264934A5083228843 @default.
- W4307264934 hasBestOaLocation W43072649341 @default.
- W4307264934 hasConcept C122927707 @default.
- W4307264934 hasConcept C126322002 @default.
- W4307264934 hasConcept C134018914 @default.
- W4307264934 hasConcept C171089720 @default.
- W4307264934 hasConcept C2776264508 @default.
- W4307264934 hasConcept C2779761222 @default.
- W4307264934 hasConcept C2780745355 @default.
- W4307264934 hasConcept C502942594 @default.
- W4307264934 hasConcept C526584372 @default.
- W4307264934 hasConcept C71924100 @default.
- W4307264934 hasConcept C98274493 @default.
- W4307264934 hasConceptScore W4307264934C122927707 @default.
- W4307264934 hasConceptScore W4307264934C126322002 @default.
- W4307264934 hasConceptScore W4307264934C134018914 @default.
- W4307264934 hasConceptScore W4307264934C171089720 @default.
- W4307264934 hasConceptScore W4307264934C2776264508 @default.
- W4307264934 hasConceptScore W4307264934C2779761222 @default.
- W4307264934 hasConceptScore W4307264934C2780745355 @default.
- W4307264934 hasConceptScore W4307264934C502942594 @default.
- W4307264934 hasConceptScore W4307264934C526584372 @default.
- W4307264934 hasConceptScore W4307264934C71924100 @default.
- W4307264934 hasConceptScore W4307264934C98274493 @default.
- W4307264934 hasFunder F4320309612 @default.
- W4307264934 hasFunder F4320321001 @default.
- W4307264934 hasFunder F4320325338 @default.
- W4307264934 hasIssue "11" @default.
- W4307264934 hasLocation W43072649341 @default.
- W4307264934 hasLocation W43072649342 @default.
- W4307264934 hasLocation W43072649343 @default.
- W4307264934 hasOpenAccess W4307264934 @default.
- W4307264934 hasPrimaryLocation W43072649341 @default.
- W4307264934 hasRelatedWork W1964688190 @default.
- W4307264934 hasRelatedWork W1978718098 @default.
- W4307264934 hasRelatedWork W2017606817 @default.
- W4307264934 hasRelatedWork W2027098794 @default.
- W4307264934 hasRelatedWork W2049045125 @default.
- W4307264934 hasRelatedWork W2071032213 @default.
- W4307264934 hasRelatedWork W2081564223 @default.
- W4307264934 hasRelatedWork W2158864582 @default.